YOU&i™ helps many people taking IMBRUVICA® get support during treatment.

Video Transcript

Narrator: This video is brought to you by the YOU&i™ Support Program. Information, support, and resources for your treatment with IMBRUVICA® (ibrutinib). The characters and story in this video are not real but are inspired by real people and situations.

[Text on screen] Information, support, and resources for your treatment with IMBRUVICA®. The characters and story in this video are not real but are inspired by real people and situations. This video is sponsored by Pharmacyclics LLC and Janssen Biotech, Inc. Please watch and consider the Important Side Effect Information at the end of this video.

Narrator: Meet Eugene and Eileen. Eugene has been taking IMBRUVICA® for a while now and he feels pretty good about sticking to his treatment plan. That’s because he had resources and support to help him take his medicine as his doctor prescribed.

Eugene: When I was first prescribed IMBRUVICA®, there was a lot to consider. To start, we weren’t sure how much it would cost. But IMBRUVICA® offered some resources for questions about insurance coverage and cost. 

[Text on screen] Call an Access Specialist to learn more about your insurance coverage and out-of-pocket costs for IMBRUVICA®. 1-877-877-3536 Monday-Friday, 8:00 AM-8:00 PM and Saturday, 8:00 AM-5:00 PM ET

Eugene: We were able to call someone—an Access Specialist—who checked how our insurance plan covered IMBRUVICA® and estimated what we’d pay out of pocket.

Narrator: When Eugene received his prescription, he and Eileen had some new questions. Eugene’s doctor had given him a lot of information, like directions for taking IMBRUVICA® and a list of possible side effects. And he also mentioned the YOU&i™ Support Program, which had helped other people who take IMBRUVICA® get information and support during treatment.

[Text on screen] What if I forget to take it? Are there foods I can’t eat? What time should I take it?

Eugene: If it helped other people, it could help me too, right? So, I went online. It was easy to sign up for the support options I wanted. 

[Text on screen] Visit www.youandisupport.com

Eugene: And once I was signed up for the support options I wanted, I got a call from a YOU&i™ Nurse Educator. She helped me better understand how to take IMBRUVICA® as my doctor prescribed and told me about some other resources on the YOU&i™ website. 

[Text on screen] Speak with a YOU&i™ Nurse Educator when it’s convenient for you. Call 1-877-877-3536 Monday-Friday, 8:00 AM-8:00 PM ET. YOU&i™ Nurse Educators do not replace medical advice from your doctor.

Eugene: We also talked about how we could set up times to talk in case I had more questions about IMBRUVICA®, or just to check in. It felt good to have another person there to help if I needed it. I’m glad I signed up for YOU&i™. Because when I thought I was having a side effect in the first couple of weeks, I had a plan for how to talk to my healthcare team about it. 

[Text on screen] Try writing down how you feel so you can talk to your healthcare team. Always talk to your doctor if you think you’re having side effects.

Eugene: I even got an email about some of the possible side effects. 

[Text on screen] YOU&i™ emails are sent periodically about topics relevant to you.

Eugene: The YOU&i™ resources helped me feel ready to have a conversation with my healthcare team at my next appointment. 

[Text on screen] Always tell your healthcare team if you think you’re experiencing side effects.

Eugene: As soon as I was prescribed IMBRUVICA®, YOU&i™ was there when I needed it.

[Text on screen] It’s easy to sign up for support. Visit www.youandisupport.com. Call 1-877-877-3536 Monday-Friday, 8:00 AM-8:00 PM and Saturday, 8:00 AM-5:00 PM ET

Narrator: YOU&i™ is with you along the way. If you—or your family or friends—have questions during your treatment with IMBRUVICA®, sign up for the YOU&i™ Support Program today.

[Text on screen] © Pharmacyclics LLC 2020 © Janssen Biotech, Inc. 2020 

YOU&i Support Program Logo (white)

The YOU&i™ Support Program is with you along the way.

Sign Up for Support

If you haven’t been prescribed IMBRUVICA® yet, visit www.imbruvica.com to learn more about IMBRUVICA® as a potential treatment option.

IMPORTANT SIDE EFFECT INFORMATION

Before taking IMBRUVICA®, tell your healthcare provider about all of your medical conditions, including if you:

  • have had recent surgery or plan to have surgery. Your healthcare provider may stop IMBRUVICA® for any planned medical, surgical, or dental procedure.
  • have bleeding problems
  • have or had heart rhythm problems, smoke, or have a medical condition that increases your risk of heart disease, such as high blood pressure, high cholesterol, or diabetes
  • have an infection
  • have liver problems
  • are pregnant or plan to become pregnant. IMBRUVICA® can harm your unborn baby. If you are able to become pregnant, your healthcare provider will do a pregnancy test before starting treatment with IMBRUVICA®. Tell your healthcare provider if you are pregnant or think you may be pregnant during treatment with IMBRUVICA®.
    • Females who are able to become pregnant should use effective birth control (contraception) during treatment with IMBRUVICA® and for 1 month after the last dose.
    • Males with female partners who are able to become pregnant should use effective birth control, such as condoms, during treatment with IMBRUVICA® and for 1 month after the last dose.
  • are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with IMBRUVICA® and for 1 week after the last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking IMBRUVICA® with certain other medicines may affect how IMBRUVICA® works and can cause side effects.

How should I take IMBRUVICA®?

  • Take IMBRUVICA® exactly as your healthcare provider tells you to take it.
  • Take IMBRUVICA® 1 time a day.
  • Swallow IMBRUVICA® capsules or tablets whole with a glass of water.
  • Do not open, break or chew IMBRUVICA® capsules.
  • Do not cut, crush or chew IMBRUVICA® tablets.
  • Take IMBRUVICA® at about the same time each day.
  • If you miss a dose of IMBRUVICA® take it as soon as you remember on the same day. Take your next dose of IMBRUVICA® at your regular time on the next day. Do not take extra doses of IMBRUVICA® to make up for a missed dose.
  • If you take too much IMBRUVICA® call your healthcare provider or go to the nearest hospital emergency room right away.

What should I avoid while taking IMBRUVICA®?

  • You should not drink grapefruit juice, eat grapefruit, or eat Seville oranges (often used in marmalades) during treatment with IMBRUVICA®. These products may increase the amount of IMBRUVICA® in your blood.

What are the possible side effects of IMBRUVICA®?

IMBRUVICA® may cause serious side effects, including:

  • Bleeding problems (hemorrhage) are common during treatment with IMBRUVICA®, and can also be serious and may lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your healthcare provider if you have any signs of bleeding, including: blood in your stools or black stools (looks like tar), pink or brown urine, unexpected bleeding, or bleeding that is severe or that you cannot control, vomit blood or vomit looks like coffee grounds, cough up blood or blood clots, increased bruising, dizziness, weakness, confusion, change in your speech, or a headache that lasts a long time or severe headache.
  • Infections can happen during treatment with IMBRUVICA®. These infections can be serious and may lead to death. Tell your healthcare provider right away if you have fever, chills, weakness, confusion, or other signs or symptoms of an infection during treatment with IMBRUVICA®.
  • Decrease in blood cell counts. Decreased blood counts (white blood cells, platelets, and red blood cells) are common with IMBRUVICA®, but can also be severe. Your healthcare provider should do monthly blood tests to check your blood counts.
  • Heart problems. Serious heart rhythm problems (ventricular arrhythmias, atrial fibrillation, and atrial flutter), heart failure, and death have happened in people treated with IMBRUVICA®, especially in people who have an increased risk for heart disease, have an infection, or who have had heart rhythm problems in the past. Tell your healthcare provider if you get any symptoms of heart problems, such as feeling as if your heart is beating fast and irregular, lightheadedness, dizziness, shortness of breath, swelling of the feet, ankles, or legs, chest discomfort, or you faint. If you develop any of these symptoms, your healthcare provider may do a test to check your heart (ECG) and may change your IMBRUVICA® dose.
  • High blood pressure (hypertension). New or worsening high blood pressure has happened in people treated with IMBRUVICA®. Your healthcare provider may start you on blood pressure medicine or change current medicines to treat your blood pressure.
  • Second primary cancers. New cancers have happened during treatment with IMBRUVICA®, including cancers of the skin or other organs.
  • Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS.

The most common side effects of IMBRUVICA® in adults with B-cell malignancies (MCL, CLL/SLL, WM and MZL) include:

  • diarrhea
  • tiredness
  • muscle and bone pain
  • rash
  • bruising

The most common side effects of IMBRUVICA® in adults with cGVHD include:

  • tiredness
  • bruising
  • diarrhea
  • mouth sores (stomatitis)
  • muscle spasms
  • nausea
  • pneumonia

Diarrhea is a common side effect in people who take IMBRUVICA®. Drink plenty of fluids during treatment with IMBRUVICA® to help reduce your risk of losing too much fluid (dehydration) due to diarrhea. Tell your healthcare provider if you have diarrhea that does not go away.

These are not all the possible side effects of IMBRUVICA®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of IMBRUVICA®

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use IMBRUVICA® for a condition for which it was not prescribed. Do not give IMBRUVICA® to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about IMBRUVICA® that is written for health professionals.

Please see the full Important Product Information.

USES

What is IMBRUVICA® (ibrutinib)?

IMBRUVICA® (ibrutinib) is a prescription medicine used to treat adults with:

  • Mantle cell lymphoma (MCL) who have received at least one prior treatment
  • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)
  • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion
  • Waldenström’s macroglobulinemia (WM)
  • Marginal zone lymphoma (MZL) who require a medicine by mouth or injection (systemic therapy) and have received a certain type of prior treatment
  • Chronic graft versus host disease (cGVHD) after failure of 1 or more lines of systemic therapy

It is not known if IMBRUVICA® is safe and effective in children.

IMPORTANT SIDE EFFECT INFORMATION

USES

Your use of the information on this site is subject to the terms of the Legal Notice and new Privacy Policy of Pharmacyclics LLC. This site is published by Pharmacyclics LLC which has developed the content in conjunction with Janssen Biotech, Inc. Any information that is collected on this site may be shared between Pharmacyclics LLC and Janssen Biotech, Inc. This information is intended for use by our customers, patients, and healthcare professionals in the United States and Puerto Rico only. Pharmacyclics LLC recognizes that the Internet is a global communication medium; however laws, regulatory requirements, and medical practices vary from country to country.

IMBRUVICA® (ibrutinib) is covered by U.S. Patents, which are listed in FDA's Orange Book (available at https://www.accessdata.fda.gov/scripts/cder/ob/default.cfm).

© Pharmacyclics LLC 2021 © Janssen Biotech, Inc. 2021 01/21 PRC-07493